Cargando…

Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells

BACKGROUND: Oligosaccharides of glycoprotein, particularly negatively-charged sialylated N-glycans, on the surface of lymphomas play important roles in cell–cell interactions and bind immunoglobulin-like lectins, causing inflammatory responses and bioregulation. However, their characterizations have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takashima, Yasuo, Yoshimura, Takeshi, Kano, Yuichiro, Hayano, Azusa, Hondoh, Hiroaki, Ikenaka, Kazuhiro, Yamanaka, Ryuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739943/ https://www.ncbi.nlm.nih.gov/pubmed/31510952 http://dx.doi.org/10.1186/s12885-019-6129-8

Ejemplares similares

MicroRNA signature constituted of miR-30d, miR-93, and miR-181b is a promising prognostic marker in primary central nervous system lymphoma
por: Takashima, Yasuo, et al.
Publicado: (2019)

miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma
por: Takashima, Yasuo, et al.
Publicado: (2020)

Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma
por: Takashima, Yasuo, et al.
Publicado: (2018)

Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma
por: Takashima, Yasuo, et al.
Publicado: (2021)

CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme
por: Takashima, Yasuo, et al.
Publicado: (2019)

Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma
por: Takashima, Yasuo, et al.
Publicado: (2018)

Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review
por: Yamanaka, Ryuya, et al.
Publicado: (2017)

Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL
por: Takashima, Yasuo, et al.
Publicado: (2019)

GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL
por: Takashima, Yasuo, et al.
Publicado: (2020)

Experiences and Expectations for Glioma Immunotherapeutic Approaches
por: Yamanaka, Ryuya, et al.
Publicado: (2014)

Promising Prognosis Marker Candidates on the Status of Epithelial–Mesenchymal Transition and Glioma Stem Cells in Glioblastoma
por: Takashima, Yasuo, et al.
Publicado: (2019)

High‐dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma
por: Akiyama, Hiroki, et al.
Publicado: (2016)

Primary central nervous system lymphoma in a rheumatoid arthritis patient treated with methotrexate: a case report
por: Shimada, Hiromi, et al.
Publicado: (2015)

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma
por: Fan, Ni, et al.
Publicado: (2017)

Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma
por: Wang, Yi-Xia, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

A Potential Serum N-glycan Biomarker for Hepatitis C Virus-Related Early-Stage Hepatocellular Carcinoma with Liver Cirrhosis
por: Higashi, Mikito, et al.
Publicado: (2020)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma
por: Lee, Bryan S., et al.
Publicado: (2014)

Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma
por: Song, Kyung Mee, et al.
Publicado: (2018)

Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma
por: Fujimoto, Kenji, et al.
Publicado: (2020)

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma
por: Bernard, S., et al.
Publicado: (2021)

Primary Central Nervous System T-cell Lymphoma as Methotrexate-associated Lymphoproliferative Disorders: Case Report
por: KAWANO, Hiroto, et al.
Publicado: (2021)

A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma
por: Villanueva, Gabriela, et al.
Publicado: (2023)

Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma
por: Zhao, Defeng, et al.
Publicado: (2014)

Hyperosmolar and methotrexate therapy avoiding surgery in the acute presentation of primary central nervous system lymphoma: Erratum
Publicado: (2014)

Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma
por: Sun, Xuefei, et al.
Publicado: (2017)

Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

Hypopituitarism and Central Diabetes Insipidus Caused by Central Nervous System Lymphoma
por: Zenimaru, Yasuo, et al.
Publicado: (2018)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma
por: Mao, Junjun, et al.
Publicado: (2022)

Combined Modality Treatment Including Methotrexate-Based Chemotherapy For Primary CENTRAL Nervous System Lymphoma: A Single Institution Experience
por: Hohaus, Stefan, et al.
Publicado: (2009)

Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort
por: Cobert, Julien, et al.
Publicado: (2009)

Factors Influencing the Response to High Dose Methotrexate-based Vincristine and Procarbazine Combination Chemotherapy for Primary Central Nervous System Lymphoma
por: Sung, Kang Hyun, et al.
Publicado: (2011)

Urine volume to hydration volume ratio is associated with pharmacokinetics of high‐dose methotrexate in patients with primary central nervous system lymphoma
por: Isono, Tetsuichiro, et al.
Publicado: (2021)

Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
por: Luo, Qian, et al.
Publicado: (2021)

P1223: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN（ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE)
por: Tang, Y.
Publicado: (2022)

PB2315: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZR OR ZRM REGIMEN (ZANUBRUTINIB, RITUXIMAB, METHOTREXATE)
por: Teng, Yue, et al.
Publicado: (2023)

Low-Dose Whole Brain Radiotherapy with Tumor Bed Boost after Methotrexate-Based Chemotherapy for Primary Central Nervous System Lymphoma
por: Kim, Byoung Hyuck, et al.
Publicado: (2014)

Advantages of Dose-Dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution
por: Aoki, Hiroshi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_buv3hsh6un5e43okclfsbj75ir